leo 142397
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2019 (NCT03995550)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Jak1 proteinINHIBITOR
JAK1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07093008 | Phase 1 | Jun 13, 2025 | AQILION AB |
| NCT05485779 | Phase 1 | Jul 20, 2022 | AQILION AB |
| NCT03995550 | Phase 1 | Aug 1, 2019 | Leo Pharma |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AQILION AB | For profit | 2 | 2 | 1 | 2022 |
| Leo Pharma | For profit | 1 | 1 | 1 | 2019 |
2 organizations
Page 1 / 1